Perfusion CT-PET: Opportunities for combined assessment of tumor vascularity and metabolism

Multi-Detector Computed Tomography in Oncology: CT Perfusion Imaging

Volumn , Issue , 2007, Pages 215-229

  Miles, Kenneth A ^a  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880151939     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (46)

1. Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med 2004; 45(Suppl) 1: 56S-65S.
2. Bacharach SL, Libutti SK, Carrasquillo JA. Measuring tumor blood flow with H(2)(15)O: practical considerations. Nucl Med Biol 2000; 27: 671-767.
3. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002; 8(4 Suppl): S62-7.
4. Raghunand N, Gatenby RA, Gillies RJ. Microenvironmental and cellular consequences of altered blood flow in tumors. Br J Radiol 2003; 76: 11-22.
5. van Laarhoven HW, Kaanders JH, Lok J et al. Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. Int J Radiat Oncol Biol Phys 2006; 64: 473-82.
6. Foo SS, Abbott DF, Lawrentschuk N, Scott AM. Functional imaging of intratumoral hypoxia. Mol Imaging Biol 2004; 6: 291-305.
7. Rajendran JG, Wilson DC, Conrad EU et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003; 30: 695-704.
8. Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma. Cancer 1998; 83: 918-24.
9. Vansteenkiste JF, Stroobants SG, Dupont PJ et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999; 17: 3201-6.
10. Higashi K, Ueda Y, Arisaka Y et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002; 43: 39-45.
11. Jeong HJ, Min JJ, Park JM et al. Determination of the prognostic value of [(18)F] fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 2002; 23: 865-70.
12. Downey RJ, Akhurst T, Gonen M et al. Preoperative F-18 fluorodeoxyglucosepositron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004; 22: 3255-60.
13. Fontanini G, Bigini D, Vignati S et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer J Pathol 1995; 177: 57-63.
14. Meert AP, Paesmans M, Martin B et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2002; 87: 694-701.
15. Tanaka F, Yanagihara K, Otake Y, et al. Prognostic factors in resected pathologic (p-) stage IIIA-N2, non-small-cell lung cancer. Ann Surg Oncol 2004; 11: 612-18.
16. Giatromanolaki A, Koukourakis MI, Sivridis E et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival. Br J Cancer 2001; 85: 881-90.
17. Aronen HJ, Pardo FS, Kennedy DN et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000; 6: 2189-200.
18. Mankoff DA, Dunnwald LK, Gralow JR et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002; 43: 500-9.
19. Semple SI, Gilbert FJ, Redpath TW et al. The relationship between vascular and metabolic characteristics of primary breast tumors. Eur Radiol 2004; 14: 2038-45.
20. Fukuda K, Taniguchi H, Koh T, Kunishima S, Yamagishi H. Relationships between oxygen and glucose metabolism in human liver tumors: positron emission tomography using (15)O and (18)F-deoxyglucose. Nucl Med Commun 2004; 25: 577-83.
21. van Laarhoven HW, de Geus-Oei LF, Wiering B et al. Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. Radiology 2005; 237: 181-8.
22. Tateishi U, Nishihara H, Tsukamoto E et al. Lung tumors evaluated with FDGPET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr 2002; 26: 185-90.
23. Hoekstra CJ, Stroobants SG, Hoekstra OS et al. Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography. Clin Cancer Res 2002; 8: 2109-15.
24. Miles KA, Griffiths MR, Keith CJ. Blood flow-metabolic relationships are dependent on tumor size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging 2006; 33: 22-8.
25. Veronesi G, Landoni C, Pelosi G et al. Fluoro-deoxi-glucose uptake and angiogenesis are independent biological features in lung metastases. Br J Cancer 2002; 86: 1391-5.
26. Swensen SJ, Viggiano RW, Midthun DE et al. Lung nodule enhancement at CT: multicenter study. Radiology 2000; 214: 73-80.
27. Yamashita K, Matsunobe S, Tsuda T et al. Intratumoral necrosis of lung carcinoma: a potential diagnostic pitfall in incremental dynamic computed tomography analysis of solitary pulmonary nodules? J Thorac Imaging 1997; 12: 181-7.
28. Miles KA, Griffiths MR, Fuentes MA. Standardized perfusion value: universal CT contrast enhancement scale that correlates with FDG PET in lung nodules. Radiology 2001; 220: 548-53.
29. Hermans R, Meijerink M, Van den Bogaert W et al. Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 1351-6.
30. 18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 2004; 5: 1295-300.
31. Devries AF, Griebel J, Kremser C et al. Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res 2001; 61: 2513-16.
32. Sahani DV, Kalva SP, Hamberg LM et al. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 2005; 234: 785-92.
33. Oku S, Nakagawa K, Momose T et al. FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer. Ann Nucl Med 2002; 16: 409-16.
34. Herbst RS, Mullani NA, Davis DW et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002; 20: 3804-14.
35. Mankoff DA, Dunnwald LK, Gralow JR et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003; 44: 1806-14.
36. Kurdziel KA, Figg WD, Carrasquillo JA et al. Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer. Mol Imaging Biol 2003; 5: 86-93.
37. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGFspecific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-7.
38. Miles KA. Computed tomography measurements of perfusion in cancer therapy. In: Shields AF, Price P, eds. In vivo Imaging of Cancer Therapy Totowa, NJ: Humana Press, 2007: in press.
39. Choi Y, Hawkins RA, Huang SC et al. Evaluation of the effect of glucose ingestion and kinetic model configurations of FDG in the normal liver. J Nucl Med 1994; 35: 818-23.
40. Miles KA, Comber L, Keith CJ et al. Combining perfusion CT and FDG-PET data demonstrates reduced hepatic phosphorylation of glucose in patients with advanced colorectal cancer and poor survival. Eur Radiol 2003; 13(Suppl 1): 293.
41. Munk OL, Bass L, Roelsgaard K et al. Liver kinetics of glucose analogs measured in pigs by PET: importance of dual-input blood sampling. J Nucl Med 2001; 42: 795-801.
42. Tayek JA. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 1992; 11: 445-56.
43. Capra S, Ferguson M, Ried K. Cancer: impact of nutrition intervention outcome-nutrition issues for patients. Nutrition 2001; 17: 769-72.
44. Laviano A, Meguid MM, Inui A, Muscaritoli M, Rossi-Fanelli F. Therapy insight: cancer anorexia-cachexia syndrome-when all you can eat is yourself. Nat Clin Pract Oncol 2005; 2: 158-65.
45. Warburg O, Wind F, Negelin E. The metabolism of tumors in the body. J Gen Physiol 1927; 8: 519-30.
46. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.